Lilly’s unstoppable growth continues, with revenue surging 39% as demand for its top-selling GLP-1 medicines drives another strong performance

Lilly’s unstoppable growth continues, with revenue surging 39% as demand for its top-selling GLP-1 medicines drives another strong performance